Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market

 
• By Aidan Fry
  
PieChart
Coherus believes its Udenyca biosimilar can take at least 20% of the US pegfilgrastim market by the end of this year • Source: Shutterstock

More from Biosimilars

More from Products